Copper-67-Labeled Bombesin Peptide for Targeted Radionuclide Therapy of Prostate Cancer
Pharmaceuticals, ISSN: 1424-8247, Vol: 15, Issue: 6, Page: 728
2022
- 22Citations
- 21Usage
- 15Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations22
- Citation Indexes20
- 20
- CrossRef18
- Patent Family Citations2
- Patent Families2
- Usage21
- Downloads18
- Abstract Views3
- Captures15
- Readers15
- 15
- Mentions1
- Blog Mentions1
- Blog1
Article Description
The gastrin-releasing peptide receptor (GRPR) is a promising molecular target for imaging and therapy of prostate cancer using bombesin peptides that bind to the receptor with high affinity. Targeted copper theranostics (TCTs) using copper radionuclides,Cu for imaging andCu for therapy, offer significant advantages in the development of next-generation theranostics. [Cu]Cu-SAR-BBN is in clinical development for PET imaging of GRPR-expressing cancers. This study explores the therapeutic efficacy of [Cu]Cu-SAR-BBN in a pre-clinical mouse model. The peptide was radiolabeled withCu, and specific binding of the radiolabeled peptide towards GRPR-positive PC-3 prostate cancer cells was confirmed with 52.2 ± 1.4% total bound compared to 5.8 ± 0.1% with blocking. A therapy study with [Cu]Cu-SAR-BBN was conducted in mice bearing PC-3 tumors by injecting 24 MBq doses a total of six times. Tumor growth was inhibited by 93.3% compared to the control group on day 19, and median survival increased from 34.5 days for the control group to greater than 54 days for the treatment group. The ease and stability of the radiochemistry, favorable biodistribution, and the positive tumor inhibition demonstrate the suitability of this copper-based theranostic agent for clinical assessment in the treatment of cancers expressing GRPR.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85132195449&origin=inward; http://dx.doi.org/10.3390/ph15060728; http://www.ncbi.nlm.nih.gov/pubmed/35745647; https://www.mdpi.com/1424-8247/15/6/728; https://digitalcommons.wustl.edu/oa_3/60; https://digitalcommons.wustl.edu/cgi/viewcontent.cgi?article=1001&context=oa_3; https://dx.doi.org/10.3390/ph15060728
MDPI AG
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know